A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

NCT00451958 ↗

Phase 3 Completed 386 enrolled Ferring Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

Summary

Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.

Timeline

Start: 2007-03
Primary completion: 2011-10
Completion: 2011-12

Publications

Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Degarelix	Other / unclassified	80 mg	Subcutaneous
Subject	Degarelix	Other / unclassified	160 mg	Subcutaneous
Background	Leuprolide	Other / unclassified	7.5 mg	Intramuscular

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Summary

Timeline

Publications

Drugs

Indications